 There are numerous difficulties with this argument, both at the level of principle and when one turns to the evidence. 205 In my view, Ranbaxy's argument requires an extension of the principles that the High Court applied in Microcell , NRDC , Philips and Ramset .
 In my opinion, the CSI Table does not contain a fair representation of all of the data available to Warner-Lambert, whether attention is focused on the CSI tests alone or whether that data is assessed in combination with the COR assays and AICS data.
 In these circumstances, Ranbaxy submitted that inutility was made out by the same matters as it advanced in support of its case of false suggestion or misrepresentation. 373 Warner-Lambert did not dispute that the specification promised that the compounds of the invention would achieve surprising and unexpected inhibition of cholesterol biosynthesis.
